Literature DB >> 11672821

Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease.

I Chemin1, D Jeantet, A Kay, C Trépo.   

Abstract

Despite a number of studies documenting hepatitis B virus (HBV) infection in the absence of hepatitis B surface antigen (HBsAg) a causal relationship between silent HBV infection and liver disease remain difficult to establish. In particular, both the prevalence and clinical significance of this observation are poorly understood. Why is HBV replication apparently so low in these patients? A number of studies have tried to elucidate the mechanism of HBsAg negative infections, and considerable data documenting HBV infectivity or reinfection in the absence of detectable HBsAg support the hypothesis that in some of these cases, HBV is undergoing low-level replication in the liver and this, in several situations including: (1) chronic liver disease, alcoholic liver disease, hepatocellular carcinoma; (2) viral reactivation following cancer chemotherapy or immunosuppression and (3) transmission via transfusion or from human serum to chimpanzees. In a recent study including 50 patients with chronic liver disease of unknown etiology we could detect serum HBV DNA by nested polymerase chain reaction (PCR) in 15/50 patients (50% at the cirrhosis stage) in the absence of HBsAg; in the liver of the 15 patients both HBcAg and/or HBsAg can be detected at very low-level. Viral host factors allowing HBV persistence in the absence of HBsAg can depend on several mechanisms. Coinfections with HCV can explain only a proportion of HBsAg(-) HBV infections. Secondly, HBV mutations in the core promotor region leading to a minimal viral replication, or mutations in the HBsAg-encoding region might explain the absence of serological recognition. Finally, it is possible that in some cases host immune mechanisms can maintain HBV infection in a latent state until transmission to another individual who subsequently develops a more active infection especially when immunosuppressive therapy is employed. Existence of HBsAg(-) HBV infections should be taken into account by the use of sensitive PCR tests for prevention of viral transmission in the settings of blood donations and organ transplants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672821     DOI: 10.1016/s0166-3542(01)00176-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

1.  Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.

Authors:  Emanuela Zappulo; Laura Ambra Nicolini; Carmen Di Grazia; Alida Dominietto; Teresa Lamparelli; Francesca Gualandi; Patrizia Caligiuri; Bianca Bruzzone; Emanuele Angelucci; Claudio Viscoli; Malgorzata Mikulska
Journal:  Infection       Date:  2018-09-19       Impact factor: 3.553

2.  Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination.

Authors:  Zohreh Borzooy; Seyed Mohammad Jazayeri; Abbass Mirshafiey; Azam Khamseh; Masoud Karkhaneh Mahmoudie; Pedram Azimzadeh; Babak Geravand; Mohammad Ali Boroumand; Mina Afshar; Vahdat Poortahmasebi; Mostafa Hosseini; Adrian Streinu-Cercel
Journal:  Germs       Date:  2015-12-02

Review 3.  Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

Authors:  Venessa Pattullo
Journal:  World J Hepatol       Date:  2015-05-08

Review 4.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

5.  Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic.

Authors:  Narcisse P Komas; Ulrich Vickos; Judith M Hübschen; Aubin Béré; Alexandre Manirakiza; Claude P Muller; Alain Le Faou
Journal:  BMC Infect Dis       Date:  2013-06-24       Impact factor: 3.090

6.  Expression of Hepatitis B Virus Surface Antigen Containing Y100C Variant Frequently Detected in Occult HBV Infection.

Authors:  Francisco C A Mello; Nora Martel; Selma A Gomes; Natalia M Araujo
Journal:  Hepat Res Treat       Date:  2011-02-06

7.  Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand.

Authors:  Olivier Galy; Isabelle Chemin; Emilie Le Roux; Stéphanie Villar; Florence Le Calvez-Kelm; Myriam Lereau; Doriane Gouas; Beatriz Vieco; Iris Suarez; Maria-Cristina Navas; Michèle Chevallier; Helene Norder; Petcharin Srivatanakul; Anant Karalak; Suleeporn Sangrajrang; Christian Trépo; Pierre Hainaut
Journal:  Hepat Res Treat       Date:  2011-06-30

8.  Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.

Authors:  Kai-Lin Chen; Jie Chen; Hui-Lan Rao; Ying Guo; Hui-Qiang Huang; Liang Zhang; Jian-Yong Shao; Tong-Yu Lin; Wen-Qi Jiang; De-Hui Zou; Li-Yang Hu; Michael Lucas Wirian; Qing-Qing Cai
Journal:  Chin J Cancer       Date:  2015-05-28

9.  Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients.

Authors:  Jer-Ming Chang; Chung-Feng Huang; Szu-Chia Chen; Chia-Yen Dai; Ming-Lun Yeh; Jee-Fu Huang; Hsing-Tao Kuo; Wan-Long Chuang; Ming-Lung Yu; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Int J Med Sci       Date:  2014-03-08       Impact factor: 3.738

10.  Occult Hepatitis B (OBH) in Clinical Settings.

Authors:  Seyed Moayed Alavian; Seyed Mohammad Miri; F Blaine Hollinger; Seyed Mohammad Jazayeri
Journal:  Hepat Mon       Date:  2012-08-25       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.